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G-protein coupled receptors (GPCRs) make up the largest family of eukaryotic 
membrane receptors, covering a broad range of cellular responses in the body.  This wide 
range of activity makes them important pharmacological targets.  In general, all Class A 
GPCRs share a common structure that consists of seven transmembrane alpha helices, 
connected by extracellular and intracellular loops, an extracellular N-terminus, and an 
intracellular C-terminus. These similarities can be used to construct a model of an 
unknown receptor, which can then be used to help guide further studies of this receptor 
and its pharmacology. 
 The orphan GPCR GPR18 is a member of the Class A subfamily of GPCRs.  
GPR18 binds both lipid-like and small molecule ligands, such as NAGly and abnormal-
cannabidiol (Abn-CBD), leading to belief that GPR18 may be the Abnormal Cannabinoid 
Receptor. The goal of this project was to construct a model of GPR18 in its inactive state 
and to explore the binding site of a key antagonist already identified for this receptor. A 
model of the GPR18 inactive (R) state was created using the -Opioid receptor (MOR) 
crystal structure as template (PDB: 4DKL). The Monte Carlo/simulated annealing 
method, Conformational Memories (CM), was used to study the accessible conformations 
of three GPR18 transmembrane helices (TMHs) with important sequence divergences 
from the MOR template: TMH3, TMH4, and TMH7.  CM was also used to calculate the 
accessible conformations for TMH6, which allowed the choice of TMH6 conformers 
appropriate for the GPR18 R and R* models.  
 
 
Docking studies were guided by the hypothesis that a positively charged residue 
(either R2.60 or R5.42) may be the primary ligand interaction site in the GPR18 binding 
pocket. The binding pocket of the antagonist, cannabidiol (CBD) was explored in the 
inactive state GPR18 model using Glide, an automatic docking program in the 
Schrödinger modeling suite.  These studies suggested that both of these arginines are 
primary interaction sites for CBD.  With the pocket determined, extracellular and 
intracellular loops were calculated using another Monte Carlo technique, Modeler.  Once 
loops were attached, the N and C termini were modeled and added as well.  The N 
terminus displayed a small helical portion that lay atop the bundle.  Together with the 
EC2 loop, this N terminus closes off the EC domains of GPR18 from the extracellular 
milieu.  This result is consistent with the structure of the S1PR1 receptor, which is closed 
to the extracellular milieu, but allows ligands to gain entry via the lipid bilayer.  With the 
identification of key residues and a complete GPR18 bundle, further mutation studies and 
dynamic simulations can be used to further refine and test these modeling results.
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CHAPTER I 
INTRODUCTION 
 
 
Background: 
Microglia are the first, and main, form of active immune defense in the central 
nervous system (CNS), and possess the ability to change receptor expression to execute 
rapid, pointed migration towards affected tissue.  Deregulation of this migration cycle 
and cellular change leads to proinflammatory and cytotoxic responses, recognized in 
several neurodegenerative diseases, such as multiple sclerosis and Alzheimer’s.1  In other 
parts of the body, like the endometrium, this cellular migration is believed to play a large 
part in the painful, and sometimes infertility causing, condition of endometriosis.2  The 
endocannabinoid system has been shown to regulate microglial migration1, and recent 
cell migration studies have found a possible new target protein, GPR18, at which the 
endocannabinoids may exert their immunomodulatory effects.2,3,4  GPR18 has recently 
been found in primary melanoma cells and in a human endometrial cell line, HEC-1B.2  
This pattern of expression suggests GPR18 as a possible therapeutic target for 
inflammatory diseases, such as endometriosis, as well as a target for neurodegenerative 
diseases such as multiple sclerosis and Alzheimer’s disease.  
 GPR18 belongs to the Class A, or Rhodopsin-like, subfamily of G-Protein 
Coupled Receptors (GPCRs).  GPCRs are transmembrane proteins that represent the 
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largest family of eukaryotic plasma membrane receptors, responsible for the majority of 
signal transduction across cell membranes.  GPCRs respond to many factors, such as 
hormones, neurotransmitters, odorants, and light, making them important 
pharmacological targets.5  There are four distinguishing characteristics of all Class-A 
GPCRs, shown in Figure 1:  
 
 
 
 
1. Seven transmembrane -helices (TMHs) 
 
2. An extracellular N-terminus 
3. Extracellular (EC) and Intracellular (IC) loops that connect each of the 
seven TMHs 
 
 
 
Figure 1. Position of Typical GPCR Within a 
Cell Membrane 
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4. An intracellular C-terminus that begins with a helical section, termed 
Helix 8, that lies parallel to the cell membrane (H8)  
 
With all GPCRs containing these same structural features, this makes comparing 
the differences all the more important.  However, Class A receptors vary in the total 
number of amino acids in their sequences.  To make comparisons easier, a new 
numbering system was constructed to describe the transmembrane sections, as the main 
length variances appear in the connecting loops.  The numbering system used here is that 
described by Ballesteros and Weinstein in 1995.6  Here, the most highly conserved 
residue in each TMH is assigned the designation of x.50.  The x is replaced by the helix 
number and the descriptor can be followed by the sequence number in parentheses.  All 
other residues within the TMH are numbered relative to this x.50 residue.  As an 
example, the most conserved residue in TMH2 is aspartic acid D2.50.  The residue 
immediately before is V2.49 and immediately after is L2.51 in the GPR18 sequence.   
 For many years, the rhodopsin crystal structure (PDB: 1GZM)7 was used as the 
template for the creation of GPCR homology models.  Recently, x-ray crystal structures 
of other Class A (Rhodopsin-like) GPCRs have become increasingly available.  These 
include meta-rhodopsin II8, the β2-adrenergic receptor (β2-AR)9, the β1 adrenergic 
receptor (β1-AR)10, the adenosine A2A receptor11, the CXCR4 receptor12, the dopamine 
D3 receptor13, the histamine H1 receptor14, S1PR1 receptor15, the nociception/orphanin 
FQ receptor16 and the ,  and  opioid receptors.17,18,19  
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Of all of the recently available GPCRs crystal structures, the -opioid receptor 
exhibits the highest sequence homology (54%) with GPR18 in key transmembrane helix 
segments.  Unlike the majority of GPCRs, for which residues within the binding pocket 
and the second EC loop partially obscure the ligand,  has a largely exposed extracellular 
opening, shown in Figure 2 in comparison with Rhodopsin.17 
 
  
 
 
 
 
 
 
Figure 2. Comparison of Extracellular Area between
A-Opioid and (B) Rhodopsin 
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Because GPR18 has been shown to recognize neutral, lipophilic ligands and small 
molecules typically bound by the cannabinoid receptors,2, 20 it is likely that GPR18 will 
exhibit a closed extracellular domain with access to the binding pocket from within the 
lipid bilayer.  This type of entry has been proposed both for the S1PR1 receptor15 and the 
cannabinoid CB2 receptor.
21,22 
 
GPCR Activation 
Information about GPCR activation has come mainly from biophysical studies on 
rhodopsin23 and the beta-2-adrenergic receptor.24,25  Within each Class A GPCR binding 
pocket, there is thought to be a set of residues that change conformation upon agonist 
binding.  These are called “toggle switch” residues and typically include residue W6.48 
of the TMH6 CWXP motif and another residue that interacts with W6.48.  Thus, when an 
antagonist binds, the ligand either directly blocks 6.48 from changing conformation, or 
causes other steric hindrances that indirectly halt a conformational change.  In the 
inactive state of rhodopsin, the χ1 dihedral of  W6.48 has been shown to be -60°, g+.7 
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This conformation is due to the close proximity of the beta-ionone ring of the covalently 
bound ligand, 11-cis-retinal, to W6.48, which locks the tryptophan in this conformation.  
When light activates rhodopsin, the ligand isomerizes into all-trans retinal.  This 
conformational shift causes the beta-ionone ring to move away from TMH6 and towards 
TMH4, allowing W6.48 to flip into a trans χ1 conformation, 180°.  This change allows 
TMH6 to flex in the CWXP hinge region and straighten.25  This straightening, in turn, 
breaks the “ionic lock” between R3.50 and E/D6.30 at the intracellular end of the 
receptor.  The result is the formation of an intracellular opening of the receptor, exposing 
residues that can interact with the C-terminus of the Gα sub-unit of the G protein.26  The 
-opioid “ionic lock” occurs in a slightly different position, between R3.50 and T6.3427, 
so it is possible that GPR18 exhibits an ionic lock with a different partner to R3.50, such 
as S6.33.   
 
  
 
Figure 3. Toggle Switch between (A) Inactive and (B) Active States 
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Ligands of GPR18 
GPR18 is similar to the cannabinoid receptors in that it binds to both small 
molecule and lipid-like ligands, shown below and in Appendix 1.  In 2006, Kohno et al 
identified eicosa-5,8,11,14-tetraenoylamino-acetic acid (N-arachidonoylglycine; NAGly) 
as the endogenous GPR18 ligand.  NAGly is structurally similar to the CB1 endogenous 
ligand N-arachidonoyl ethanolamine (AEA).20  The difference between the two lies in the 
head group region, where AEA contains an ethanolamine versus NAGly's glycine.  This 
difference renders NAGly inactive at both the CB1 and CB2 receptors.  While the 
biological functions of NAGly are not very well understood, it has been shown to have 
some analgesic properties similar to AEA, via inhibition of the hydrolytic activity of fatty 
acid amid hydrolase (FAAH) on AEA.  However, due to the level of expression of 
NAGly in a variety of tissues (e.g. skin, small intestine, kidney, testis, and brain) it likely 
is involved in other physiological functions.  Arachadonic acid-derivatives usually play a 
major role in inflammation and pain, as seen in the cannabinoid receptors.20 
 
 
 
 
 
 
 
     
 
Figure 4. Endogenous GPR18 ligand NAGly (left) compared to AEA (right) 
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GPR18 can also be activated by the atypical cannabinoid Abn-CBD, as well as several 
other cannabinoids, leading to the idea that GPR18 could be considered another 
cannabinoid receptor.1 
 
 
 
 
Cell migration assays have shown that GPR18 couples to Gi/o proteins, with an agonist 
profile including Abn-CBD, O-1602, 9-THC, and NAGly.  The observed migration can 
be blocked by O-1918, arachidonyl serine,  or cannabidiol (CBD).  This ligand profile is 
similar to that documented for a previously postulated cannabinoid receptor, the Abn-
CBD receptor, which was never cloned.  There is increasing evidence, however, that 
GPR18 may in fact be the Abn-CBD receptor.1-2   
Figure 5. Structure of Abn-CBD 
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CHAPTER II 
HYPOTHESIS & METHODS 
 
 
Goals: 
This project focused on the computational creation of a homology model of the 
GPR18 R (Inactive) state using the TMH region of the recent -opioid receptor x-ray 
crystal structure17 as a template.  Because GPR18 has important sequence divergences 
from the template in TMH3, 6, and 7, Conformational Memories (CM), the Monte-
Carlo/simulated annealing technique, was used to calculate new conformations for these 
helices.  A possible binding pocket was identified, and the small molecule cannabidiol 
(CBD) was docked in the resultant model.  Interactions surrounding the binding of this 
antagonist were analyzed to determine key binding pocket residues.  The main goal was 
to create a usable computational model to help guide further investigation into this new 
receptor through mutation and molecular dynamics studies. 
 
Methods: 
Rotameric States in Amino Acid Side Chains 
 
The rotamer nomenclature used herein is the same as that described by Shi et al in 
200024, and the basic structure shown in Figure 6. 
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 A trans χ1 angle is defined as when the heavy atom at the  position lies opposite the 
backbone nitrogen (180°), when viewed from -carbon to -carbon.  Gauche+ (g+) is 
defined as when the  heavy atom is opposite the backbone carbon and has an angle of  
-60°, while gauche- (g-) has the -carbon heavy atom opposite the -hydrogen at an angle 
of +60°, viewed along the same axis.  
 
Sequence Alignment 
As discussed above, the orphan receptor GPR18 belongs to the Class-A, or 
Rhodopsin-like, subfamily of GPCRs.  GPR18 contains the majority of the conserved 
residues of Class A GPCRs in TMHs 1, 2, 4, and 5 (N1.50, D2.50, W4.50, and P5.50), as 
well as the DRY motif in TMH3.  However, it also contains some notable differences, 
including: 1) a substitution at position 6.48 (CFXP instead of CWXP), and 2) the 
nonconservative motif DVILY instead of the TMH7 NPXXY motif.  In addition, TMH3 
in GPR18 contains a helix-altering proline residue at position 3.36.  The initial GPR18 
 
Figure 6. The χ1 angle displayed 
using Threonine 
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model was constructed by first aligning the sequence with that of other Class A GPCRs 
using the highly conserved sequence motifs or residues as the alignment guides, shown in 
Appendix 2.  The base crystal structure for the -opioid receptor (PDB: 4DKL) was 
mutated to the corresponding GPR18 sequence using Maestro (a Schrödinger Inc. 
program).  Helices that contain helix deforming residues such as prolines or glycines 
were then studied using Conformation Memories (see below) to determine possible low 
free energy conformations, and then an appropriate substitute helix was chosen to 
incorporate into the model. 
 
Conformational Memories (CM) 
In order to explore the different conformations of TMH3, TMH6, and TMH7 
dictated by their sequence divergences from the template structure, the conformational 
memories (CM) method was used. This method employs multiple Monte Carlo/simulated 
annealing random walks and the CHARMM (Chemistry at HARvard Molecular 
Mechanics) force field.28  The CM method is widely used because it converges in a 
practical number of steps and it is capable of overcoming energy barriers efficiently. The 
CM method can fully characterize the conformational properties of a helix based on their 
free energies.  This includes both the intrinsic energy of each conformational state and the 
probability that the helix will adopt a specific conformation relative to the other 
accessible conformations in an equilibrated thermodynamic ensemble.  The calculations 
are performed in two phases, the Exploratory and Biased Annealing Phases.  
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Exploratory Phase 
 In the CM method, a random walk is used to identify the region of conformational 
space most probable for each torsion angle and bond angle. The initial temperature for 
each run is 3000 K with 50,000 Monte Carlo steps applied to each torsion or bond angle 
variation with cooling in 18 steps to a final temperature of 310 K. Each step consists of 
varying two dihedrals angles and one bond angle chosen at random from the entire set of 
variable angles. Each move is the accepted or rejected using the Metropolis criterion.29  
Accepted conformations in the Exploratory Phase are used to create “memories” of 
torsion angles and bond angles that were accepted.  This information provides a map of 
the accessible conformational space of each TMH as a function of temperature. 
 
Biased Annealing Phase 
In the second phase of the CM calculations, the only torsion angles and bond 
angles moves attempted are those that would keep the angle in the “populated 
conformational space” mapped in the exploratory phase. The biased annealing phase 
begins at 749.4 K cooling to 310 K in 7 steps. Finally, 120 structures are output at 310 K 
for each TMH studied. 
 
Identification of TMHs for CM Study 
For the GPR18 model, the base -Opioid model required CM studies of three of 
helices: TMH3, TMH6, and TMH7.  TMH3 would differ due to a proline at position 3.36, 
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which is unmatched in the  sequence.  For TMH6, GPR18 has a CFXP motif in TMH6, 
rather than the typical Class A CWXP motif as in the -opioid receptor.  The difference of 
the W→F change at 6.48 and the added bulk of a T→M change at 6.49 would induce a 
change in the helix conformation, which would be amplified further by the need to 
accommodate the following bulk of an F at 6.51 and an H at 6.52 in GPR18.  Lastly, 
calculation of a new conformation for TMH7 was necessitated by the lack of the highly 
conserved P7.50 in GPR18, as well as an altered motif, DVILY rather than the more 
conserved NPXXY in the -opioid receptor. 
 
CM Study of GPR18 TMH3, TMH6, and TMH7 
 Models of TMH3, TMH6, and TMH7 were created using the CM technique.  The 
backbone dihedrals of each -helix were set to the standard φ (-63°) and ψ (-41.6°) for 
TMHs as described by Ballesteros and Weinstein in 1995.6  Our established protocol is to 
allow all torsion angles to vary ±10°, and to allow a larger variation of ±50° in regions 
containing helix bending residues such as prolines, glycines, serines and/or threonines.30  
Individual bond angles were allowed to vary ±8°, and the following were allowed to vary 
±15°:  C-O-H on Ser, Thr and Tyr; C-N-H on Trp, His, Gln, Asn and Lys; C-S-H on Cys 
and C-S-C on Methionine.28  These bond angle variations are used since certain residues 
and sulfur atoms can accommodate bond angle changes, while aliphatic hydrogen bond 
angles were not varied.  
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TMH3: All GPCRs were aligned using the conserved motif of E/DRY in TMH3.  GPR18 
has a unique proline at position 3.36.  No other Class A GPCR has a proline at this 
position, so the bend introduced into the helical structure has no previous structural 
match. To allow for helix distortion, the region of i (P3.36) to i-4 (T3.32) was considered 
“flexible,” with the phi and psi values in this area allowed to vary by ±50°. 
 
TMH6: TMH6 contains a very similar flexible motif, CFXP, compared to the Class A 
GPCR conserved motif of CWXP.  However, GPR18 has a methionine at position 6.49, 
which is a fairly bulky residue.  There are also a couple of bulky residues after the CFMP 
region, which would have to be accommodated by the new output.  Previous studies show 
that W6.48 is a “toggle switch” for activation, χ1 is in a g+ position in the R state, and in 
trans in the R* state.24  Conformational Memories outputs were used to select an 
appropriate helix for an R and R* model.  In TMH6 CM calculations, the i (P6.50) to i-4 
(V6.46) region was allowed to vary by ±50°. 
 
TMH7: The -opioid receptor contains the Class A GPCR conserved motif of NPXXY.  
However, GPR18 contains neither the conserved P7.50 nor the motif of NPXXY.  To 
account for possible changes in conformation due to this sequence variance, the flexible 
region of i (V7.50) to i-4 (T7.46) was chosen and allowed to vary by ±50° in the 
Conformational Memories run. 
 
15 
 
Superimposition and Determination of Helices 
The base template bundle of the -opioid receptor had its sequence mutated to 
that of GPR18.  The resultant initial model was then was pulled apart by 2Å to allow 
room for the side chains to accommodate each other in the new bundle. For each 
Conformation Memories study, all 120 output conformations were superimposed onto the 
corresponding template helix in the initial GPR18 model.  For all superimpositions 
described, the C's of the sequence up to the flexible region were used as the basis for the 
superimposition.   
Once the outputs were superimposed upon the initial model, an appropriate helix 
was chosen after eliminating helices that had steric clashes with the binding pocket.  
Helix 3 was superimposed from the intracellular residues up to S3.37, the residue 
immediately preceding the proline.  With the conformational change in TMH6 between R 
and R* states, the CM outputs were sorted based on the 1 angle of F6.48.  The g+ (-60° 
range) were superimposed onto the base helix at the intracellular end, from K6.30 to 
L6.45; while those with the χ1 angle trans (for the R* model), the outputs were 
superimposed on the extracellular end of the temple helix, from F6.51 to G6.61.  For 
TMH6, the R helix chosen was based on the presence of F6.48 χ1 in a g+ position, and 
ability to form the TMH3/TMH6 ionic lock (R3.50/S6.33 for GPR18) characteristic of 
the inactive state.  The chosen R* helix fit the requirements that the TMH3/TMH6 ionic 
lock must be broken and that the χ1 angle of F6.48 be in a trans position.  For TMH7, the 
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outputs were superimposed on the extracellular region down to S7.45, the residue 
immediately before the i-4 residue of T7.46. 
 
Ligand Docking Protocol 
Before docking cannabidiol (CBD), an AM-1-conformational search was 
performed to identify its global minimum energy conformation.  The global min was then 
used for docking studies via the automatic docking program, Glide (Schrodinger Inc.).  
Glide generates a grid based on the centroid of select residues in the binding site (from 
the manual dock).31  In GPR18, R5.42 was used as the primary interaction site to help 
position CBD in an antagonist position over 6.48.  The resulting ligand/receptor complex 
was energy minimized using CHARMM, in the same process as described below. 
 
Minimization Protocol 
Each bundle was pulled apart 2Å away from a central point to allow room for the 
side chains to accommodate each other in the new bundle.  Once the new helices were 
chosen and inserted into the receptor bundle, each residue was adjusted manually to its 
most energetically favorable position, while allowing room for all other residues and 
preventing any Van der Waals conflicts.  The χ1 torsion angles of C6.47, W6.48 and 
H6.52 were adjusted to trans/g+/g+ respectively to be in agreement with the “toggle 
switch” proposed by Shi and co-workers.24  Also, R3.50 and S6.33 were oriented towards 
each other to promote the formation of the ionic lock when the bundle is minimized. The 
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distance between the first nitrogen of the guanidine group of R3.50 and the hydroxyl 
oxygen of S6.33 was constrained to a distance of 2.8Å ± 0.4Å with a force of 15kJ/mol.  
Once all Van der Waals overlaps had been relieved, the minimization was started using 
an OPLS_2005 force field, no solvent, and a distance dependent dielectric.  All backbone 
phi / psi dihedrals were constrained with a force of 500kJ/mol, while the amino acid side 
chains of each residue were allowed to vary.  Minimizations were performed with the 
docked ligand CBD present, as previous attempts of minimizing the bundle in the 
absence of ligand resulted in collapse of the binding pocket.  
 
Loop and Termini Methodology 
Once appropriate substitute helices for TMH3, 4, 6, and 7 were chosen, loop 
segments were built and added to the models using Modeler.  This Monte Carlo technique 
developed by Fiser and co-workers uses a template library of possible side chain 
conformations from the Protein Data Bank for all amino acids.32  Using the CHARMM 
force field, each loop was varied and assigned an objective function ranking value.28  This 
value is based on steric interactions and hydrogen bonding of each possible 
conformation, and the 250 lowest energy loop outputs were used for further analysis and 
selection.   
 Similar to the extracellular and intracellular loops, the N and C termini were built 
and added to the GPR18 model once the loops were complete.  The same Monte Carlo  
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technique was used to calculate possible side chain conformations.  The 250 lowest 
energy loop outputs were then sorted and analyzed to determine a final structure. 
 
Interaction Energy Calculation 
The interaction energy between the ligand, CBD, and the minimized receptor 
complex was calculated using a Molecular Mechanics tool in Maestro (Schrodinger, 
2006). The OPLS_2005 force field was used, with no solvent and a distance dependent 
dielectric.  The ligand was identified manually (selected by hand), and all residue 
interactions within 5Å of the ligand were used in the calculation.  
19 
 
CHAPTER III 
 
RESULTS 
 
 
GPR18 Model based on the -Opioid Receptor: 
An inactive (R) receptor bundle was originally constructed using the -opioid 
receptor structure as a template.  Upon studying the CM output structures for TMH3, it 
was observed that both TMH3 and 4 in the -opioid receptor were significantly bent, 
highlighted by the red dashed lines in Figure 7. 
 
 
 
This bend is due to a hydrogen bonding network between TMH3 and 4, which is 
unmatched in the GPR18 sequence.  Using the -opioid receptorTMH3 as a base for the 
 
 
Figure 7. (A) Comparison of the EC ends of TMH3 and 4 between MOR (yellow/green) and Straight 
Helices (blue). (B) Close-up of residues forming the hydrogen bonding network in MOR 
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GPR18 TMH3 would introduce a bend bias into the structure that would not fit the kink 
induced by the proline at 3.36.  
 
TMH6 
Despite GPR18's CFMP motif versus the conserved CWXP motif of other Class-
A GPCRs, the rest of the helical sequence of TMH6 does not differ substantially from 
that of the -opioid receptor template.  Thus, the CM output chosen for the inactive, or R, 
bundle has a similar conformation to that of the opioid receptor TMH6, with a wider 
bend to accommodate for the bulk of GPR18's CMFP region as well as the bulk of F6.51 
and H6.52.  The similar EC position of the helices also matches the similar loop lengths 
of both GPR18 and the -opioid receptor crystal.  However, upon docking and 
minimization, it was observed that the chosen helix could not pack well with TMH5 and 
TMH7.  Therefore, a second TMH6 output was chosen, which allowed for better packing 
with TMH7.  
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As the TMH6 for the inactive bundle was superimposed on the intracellular side, S6.33 
remained in a position to promote a possible ionic lock between it and the conserved 
residue R3.50, shown in Figure 9. 
 
Figure 8. Extracellular View of TMH6 and labeled choices 
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GPR18 Model – Ideal Helix Base Structures: 
The -opioid receptor crystal structure template has two major differences with 
GPR18 concerning TMH3. First, GPR18 contains a proline at the position 3.36 that is 
unmatched in the -opioid receptor sequence, and second, the -opioid receptor bundle is 
built to accommodate bulky ligands that enter extracellularly.  Despite varying the 
flexible region around the proline in the GPR18 model, the angles did not compensate for 
the bend already built into the template -opioid receptor TMH3. For this reason, TMH3 
was built as an ideal helix and input to Conformational Memories using the same flexible 
region, from T3.32 to P3.36. 
 
 
 
 
 
 
Figure 9. Ionic lock between R3.50 and S6.33 
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TMH3 
Figure 10 shows the TMH3 output structures (blue) superimposed intracellularly 
onto the mutated -opioid receptor base structure.  The red helix illustrated in Figure 10 
was the helix chosen for the GPR18 bundle.  
 
 
 
 
As mentioned before, the MOR crystal has a very open extracellular end to permit the 
docking of large ligands such as morphine and naloxone, which have structures very 
different from that of CBD and NAGly.  Thus, from the span of outputs, a helix was 
required that was straighter, to help constrict the extracellular side of the bundle.  
However, the helices further into the binding pocket were not chosen as we did not want 
to completely constrict the binding pocket once the bundle was minimized.  Also, there 
are aromatic residues on the top of both TMH2 and 5, which restrict how far to either side 
 
 
Figure 10. Extracellular view of TMH3 outputs and the chosen helix (red) 
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the helix can be positioned.  Lastly, due to the proline at 3.36, a TMH3 with a face shift 
needed to be chosen so that C3.25 at the EC end of TMH3 was positioned to form a 
disulfide bridge with the EC2 loop Cys(172).  This disulfide bridge is found in nearly all 
Class A GPCRs.  
 
TMH4 
TMH4 in the -opioid receptor crystal structure is bent due to a hydrogen bonding 
network it shares with TMH3 in the  structure, shown previously in Figure 7. This 
hydrogen bonding network pulls TMH4 into a bent position to match the significant bend 
in TMH3.  As GPR18's TMH3 was already altered due to the unique P3.36, TMH4 in 
GPR18 lacks any reason to be bent in the same way as in the -opioid receptor.  So a CM 
study of TMH4 was undertaken using an ideal helix as the starting structure. Comparing 
the GPR18 sequence with the -opioid receptor template resulted in the addition of 
another turn onto TMH4, so that the helix transitioned to loop at K4.65. Using an ideal 
helix as the starting structure for TMH4 permitted a choice for TMH4 that worked with 
the chosen GPR18 TMH3.  
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TMH7  
Unlike the majority of Class A GPCRs, GPR18 does not contain the conserved 
motif of NPXXY within TMH7, so the calculated output would likely have a much 
different bend in it due to the lack of a proline.  From the spread of outputs shown in 
Figure 12, there are no outputs that are similar to that of the MOR crystal base (as would 
be expected).  
 
 
Figure 11. Extracellular view of TMH4 outputs and the chosen helix (light blue) 
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When placed into the bundle, steric clashes with aromatic residues on the interface 
between TMH1 and 7 and TMH6 and 7 could be used to eliminate helices.  The helix 
chosen, shown in a light purple in Figure 12, had no steric clashes with the rest of the 
bundle, and packed well with the new TMH6 that had been chosen earlier. 
 
 
 
 
 
 
Figure 12. Extracellular view of TMH7, with the chosen helix (pale purple) 
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Ligand Conformational Searches: 
O-1918 
From studies by McHugh,1 the small molecule O-1918 was seen to antagonize the 
cell migration induced by NAGly.  Using this information, O-1918 was chosen as the 
antagonist to be used for docking studies in the newly developed GPR18 R model.  Using 
the program Spartan, the lowest energy conformation (or global min) was calculated 
using an AM-1 conformational search.   
 
 
 
From the electrostatic potential map shown in Figure 13, the methoxy oxygens appeared 
to be heavily occluded by the rest of the molecule, so we hypothesized that a cation-pi 
interaction between the aromatic ring of O-1918 and one of the two arginines facing the 
binding pocket would be the primary interaction sites.  An interaction with R2.60 left 
F6.48 with the ability to freely rotate, so R5.42 was chosen as the primary interaction 
 
Figure 13. (A) O-1918 Global Minimum Conformation. (B) Electrostatic Potential Surface of O-1918 
Global Min. 
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site.  The Glide program, Maestro (Schrodinger, 2006), calculated few conformations that 
could work as a cation-pi, but there were problems minimizing the bundle and 
maintaining the docked position.  Later information (unpublished) led to the conclusion 
that O-1918 could actually be working as an agonist within GPR18,33 and we therefore 
abandoned the O-1918 study to look for another antagonist was chosen to be docked. 
 
Cannbidiol (CBD) 
The small molecule, Cannabidiol (CBD), was chosen as the new antagonist to be 
modeled and docked within the inactive GPR18 model.2  Using the same procedure 
described above in the Methods section for O-1918, the global minimum conformation of 
CBD was calculated.  The results are summarized below in Figure 14. 
 
 
 
 
 
 
Figure 14.  (A) CBD Global Minimum Conformation. (B) Electrostatic Map of CBD Global Min. 
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As can be seen in the electrostatic potential surface, shown in Figure 14B, the oxygens of 
the hydroxyl groups are more accessible than those of O-1918’s methoxys.  Thus, instead 
of cation-pi interactions, hydrogen bond interactions were more likely.  When initially 
input into Glide, R5.42 was hypothesized to be the primary interaction site because the 
bulk of the ligand would impede the rotation of F6.48.  An orientation of the ligand was 
observed that could possibly also reach R2.60, once the bundle was minimized around 
CBD. 
   As described in the Minimization Protocol (see the Methods section), the GPR18 
bundle was minimized with CBD placed inside to maintain the binding pocket and 
prevent the bundle from collapsing on itself.  The ligand was held rigid, aside from small 
rotations of the hydroxyl groups to help maintain the hydrogen bond with R5.42 and 
possibly to find a hydrogen bond with R2.60.  Figure 15 shows the final docked position 
of CBD from an extracellular view, with the two arginines bracketing the ligand. 
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When seen from the side, through TMH1 and 7, CBD (in green) sits close to 6.48 (shown 
in grey) so that when seen in Van der Waals, there is not enough room for the phenyl side 
chain of F6.48 to rotate into an active conformation.   
 
 
 
 
Figure 15. EC View of CBD docked position 
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Loop Construction and Modeling: 
Extracellular (EC) Loops 
Once the loops were built in Maestro, they were connected to the bundle in one 
entry.  Modeler was used to calculate possible conformations for all three extracellular 
loops, in a high distance dependent dielectric (around 80) to simulate the aqueous 
environment surrounding the loops.  GPR18 has small loops, with the EC1 and EC3 
having only five and six residues respectively.  The longer EC2 loop contains a disulfide 
bridge between C(172) and C3.25, which was the only structural constraint specified.  
One characteristic seen in multiple crystal structures is that the residue two residues after 
the disulfide Cys points down into the bundle.  This was used as a screening tool to select 
 
 
Figure 16. Docked CBD (green) sitting over F6.48 (grey) 
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an appropriate EC2 loop conformation.  Despite no secondary structure being specified, 
Modeler calculated a beta-sheet within the long EC2 loop, as can be seen in Figure 17.  
 
 
 
 
Intracellular (IC) Loops 
The intracellular loops were modeled and attached in the same way as the 
extracellular loops, mentioned above, as well as using the same Modeler settings.  Unlike 
the extracellular loops, there were no structural constraints applied to the three loops.  
GPR18 has a fairly short IC1 loop, containing only five residues.  In many GPCRs, the 
IC2 loop tends to contain a small helical portion (for an example, see the beta-2 
adrenergic receptor structure)9, but due to lack of information, no region was specified 
 
Figure 17. Extracellular Loops of GPR18 Model 
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for the calculations.  Interestingly, though, Modeler showed a helical extension to TMH3 
in a majority of the outputs, despite the proline at 3.57 that usually breaks the helix into 
loop.  This extension also limits the formation of another helix within the middle of the 
loop, as seen in other crystal structures.  It is possible that when placed into a lipid 
simulation, the random coil of the loops may form into more defined structures.  
 
 
 
 
In the majority of Class A GPCR crystal structures, the IC3 loop has been broken for the 
addition of a T4-lysozyme to help stabilize the receptor.  Structural information about this 
 
Figure 18. Intracellular Loops of GPR18 Model
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loop is limited, however, no such modification is made in the rhodopsin structure.  Here 
the IC3 loop contains both TMH5 and TMH6 intracellular helical extensions.7   
 
Termini Construction and Modeling: 
Both the N and C termini were constructed in Maestro and attached to the GPR18 
Bundle once both sets of loops were chosen.  The N Terminus (18 residues) was run in 
one calculation, while the C Terminus’s length (29 residues) meant that it needed to be 
run in two smaller sections.  Again, a higher dielectric (around 80) was used to simulate 
the aqueous environment surrounding the loop regions.  No structural restrictions were 
put on the N terminal segment.  Using the example of the S1PR1 crystal structure15 and 
the proposed method for ligand access to the binding pocket via the lipid bilayer, such as 
in CB2,
22 an output was looked for that would cap the top of the bundle.  Although no 
structure was specified, one output revealed a small helical portion that covers the top of 
the bundle over TMH2 and 3.  This section, along with the EC2 loop, provides an almost 
full cover for the binding pocket. 
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The C Terminus (past Helix 8) is complicated as there is little to no structural 
information about it, from any crystal structure.  As there is no cysteine within the C 
terminus of GPR18, there is no palmitoylation site to be anchored near the bilayer.  With 
a sequence longer than fifteen residues, the terminus was split into two segments, with 
one run finished and a result chosen before adding the second section. Many of the 
outputs were culled as the resulting structure either wrapped around the bundle or tried to 
insert into the bottom of the receptor. The chosen output had the main bulk of the loop 
situated lower than Helix 8, and the curve in it supported by pi-pi stacking interactions 
between the multiple arginines and tyrosines within the tail section.  Once the first part 
was chosen, the second was added and run with the same dielectric value. 
 
Figure 19. Side view of the N Terminus with its helical portion 
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The final chosen structure is fairly compact, but not overly tight, so that it would not 
impede itself when unwinding for later signaling.  It also sits largely intracellularly, to 
help facilitate recognition for signaling. 
 
Interaction Energies: 
The interaction energies between CBD and the residues of the binding pocket 
were calculated using the final minimized dock.  The electrostatic, Van der Waals 
(VDW), and total energy of all residues within 5Å of the ligand were calculated and are 
shown in Table 1.  R2.60 contributes the highest electrostatic interaction of -17.3143 
 
 
Figure 20. Side view of the C Terminus 
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kJ/mol, while R5.42 contributes a smaller, but still significant interaction of -9.6137 
kJ/mol.  T3.32, F6.51, F6.55, and M7.42 all contribute largely to Van der Waal’s 
interactions, with F6.55 being the highest at around -30 kJ/mol.   
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Table 1. Interaction Energies between the Ligand CBD and Residues within 5Å 
 
 
Residue VDW (kJ/mol) 
Electrostatic 
(kJ/mol) 
Total Energy 
(kJ/mol) 
R 2.60 -3.2531 -17.3143 -20.5673 
C 3.25 -0.8398 -0.376 -1.2159 
L 3.28 -0.7336 0.2813 -0.4523 
G 3.29 -6.3752 1.2833 -5.0919 
A 3.30 -0.3713 0.0048 -0.3665 
T 3.32 -10.0272 -1.257 -11.2842 
V 3.33 -8.6347 -0.2797 -8.9145 
P 3.36 -2.7599 0.1115 -2.6484 
Y 4.64 -4.793 -0.1069 -4.8999 
C (EC2) -0.3639 0.1209 -0.243 
R 5.42 -3.6639 -9.6137 -13.2776 
F 5.46 -4.0412 0.1351 -3.9062 
C 6.47 -0.609 -0.102 -0.711 
F 6.48 -6.1463 0.1555 -6.3019 
F 6.51 -19.0247 -0.3412 -19.366 
H 6.52 -8.1117 -0.1239 -8.2356 
C 6.54 -0.7314 0.044 -0.6874 
F 6.55 -30.2268 -4.6937 -34.9205 
L 6.58 -4.5781 0.1418 -4.4363 
M 6.59 -2.3021 -0.0585 -2.3606 
T (EC3) -0.3173 -0.4743 -0.7916 
T 7.38 -4.9066 -0.2668 -5.1734 
T 7.39 -0.541 -0.0981 -0.6391 
M 7.42 -16.6693 -1.5228 -18.1921 
Total Energy 
(kJ/mol) 
-174.6832 
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Summary: 
A homology model of the inactive state of the orphan GPCR GPR18 was 
constructed using the recently released crystal structure of the -opioid receptor as a base 
template.  Important structural differences in TMH3, 4, and 7 meant reconstructing these 
helices using Conformational Memories, as well as calculating both active and inactive 
conformations for TMH6.  An ionic lock between S6.33 and the conserved residue of 
R3.50 was found to stabilize the inactive state of GPR18.  Using the lowest energy 
conformation of the antagonist CBD for docking studies, key interactions with both 
R2.60 and R5.42 were identified after energy minimization of the CBD/GPR18 R 
complex. In its final docked conformation, CBD blocks the conformational change of 
F6.48, thereby acting an antagonist.  In agreement with the S1PR1 crystal structure and 
the hypothesis of a transmembrane entrance into the binding pocket, the modeled N 
terminus and EC2 loop cover the EC domain of the bundle, thus blocking the ligand from 
entering the pocket extracellularly.  
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Figure 21. Transmembrane view of complete GPR18 Model 
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APPENDIX A 
 
GPR18 LIGANDS 
 
 
 
45 
 
APPENDIX B 
 
SEQUENCE ALIGNMENT 
 
 
 
Rho M N G T E G P N F Y
S1P1 M G P T S V P L V K A H R S S V S D
CB2 M E E C W V
Beta-2 M G Q P G N
MOR M D S S A A P T N A S N C T D A L A Y S S C S P A P S P G S W V N L S H L D G N L S D
GPR18
N-Ter→
Rho V P F S N A T G V V R S P F E Y P Q Y Y L A E
S1P1 Y V N Y D I I V R H Y N Y T G K L N I S A D K
CB2 T E I A N G S K D G L D S N P M K D Y M I L S
Beta-2 G S A F L L A P N R S H A P D H D V T Q Q R D
MOR P C G P N R T D L G G R D S L C P P T G S P S
GPR18 M I T L N N Q D Q P V P F N S S H P
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
2 3 3 3 3 3 3 3 3 3 3 3 4 4 4 4 4 4 4 4 4 5 5 5 5 5 5 5 5 5 5 6
9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0
Rho P W Q F S M L A A Y M F L L I V L G F P I N F L T L Y V T V Q H K K L R T
S1P1 E N S I K L T S V V F I L I C C F I I L E N I F V L L T I W K T K K F H R
Orexin K Q Y E W V L I A A Y V A V F V V A L V G N T L V C L A V W R N H Q L R R K
Beta-2 E V W V V G M G I V M S L I V L A I V F G N V L V I T A I A K F E R L Q T
MOR M I T A I T I M A L Y S I V C V V G L F G N F L V M Y V I V R Y T K M K T
GPR18 D E Y K I A A L V F Y S C I F I I G L F V N I T A L W V F S C T T K K R T
IC1 Loop
TMH1
2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
3 3 4 4 4 4 4 4 4 4 4 4 5 5 5 5 5 5 5 5 5 5 6 6 6 6 6 6 6 6
8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7
Rho P L N Y I L L N L A V A D L F M V L G G F T S T L Y T S L H G Y F V F G
S1P1 P M Y Y F I G N L A L S D L L A G V A Y T A N L L L S G A T T Y K L T
CB2 P S Y L F I G S L A G A D F L A S V V F A C S F V N F H V F H G V D S
Beta-2 V T N Y F I T S L A C A D L V M G L A V V P F G A A H I L M K M W T F G
MOR A T N I Y I F N L A L A D A L A T S T L P F Q S V N Y L M G T W P F G
GPR18 T V T I Y M M N V A L V D L I F I M T L P F R M F Y Y A K D E W P F G
TMH2 GG Motif EC1 Loop
3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3 3 4 4 4 4 4 4 4 4 4 4 5 5 5 5 5 5 5
2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6
Rho P T G C N L E G F F A T L G G E I A L W S L V V L A I E R Y V V V C K P M S N F R F
S1P1 P A Q W F L R E G S M F V A L S A S V F S L L A I A I E R Y I T M L K M K L H N G S
CB2 K A V F L L K I G S V T M T F T A S V G S L L L T A I D R Y L C L R Y P P S Y K A L L
Beta-2 N F W C E F W T S I D V L C V T A S I E T L C V I A V D R Y F A I T S P F K Y Q S L L
MOR T I L C K I V I S I D Y Y N M F T S I F T L C T M S V D R Y I A V C H P V K A L D F R
GPR18 E Y F C Q I L G A L T V F Y P S I A L W L L A F I S A D R Y M A I V Q P K Y A K E L K
TMH3 D/ERY/F Motif IC2 Loop
4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
3 3 4 4 4 4 4 4 4 4 4 4 5 5 5 5 5 5 5 5 5 5 6 6 6
8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2
Rho G E N H A I M G V A F T W V M A L A C A A P P L A
S1P1 N N F R L F L L I S A C W V I S L I L G G L P I M
CB2 T R G R A L V T L G I M W V L S A L V S Y L P L M
Beta-2 T K N K A R V I I L M V W I V S G L T S F L P I Q
MOR T P R N A K I I N V C N W I L S S A I G L P V M F
GPR18 N T C K A V L A C V G V W I M T L T T T T P L L L
TMH4
Rho G W S R Y I P E G L Q C S C G I D Y Y T L K P E V N N
S1P1 G W N C I S A L S S C S T V L P L Y H
CB2 G W T C C P R P C S E L F P L I
Beta-2 M H W Y R A T H Q E A I N C Y A N E T C C D F F T N
MOR M A T T K Y R Q G S I D C T L T F S H P T W Y W E
DOR M A V T R P R D G A V V C M L Q F P S P S W Y W D
GPR18 L Y K D P D K D S T P A T C L K I S D I I Y L K A V
GW Motif Internal loop disulfide bridge C325 disulfide bridge
5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5
3 3 3 3 4 4 4 4 4 4 4 4 4 4 5 5 5 5 5 5 5 5 5 5 6 6 6 6 6 6 6
6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6
Rho E S F V I Y M F V V H F T I P M I I I F F C Y G Q L V F T V K
S1P1 K H Y I L F C T T V F T L L L L S I V I L Y C R I Y S L V R
CB2 P N D Y L L S W L L F I A F L F S G I I Y T Y G H V L W K A H
Beta-2 Q A Y A I A S S I V S F Y V P L V I M V F V Y S R V F Q E A K
MOR N L L K I C V F I F A F I M P V L I I T V C Y G L M I L R L K
GPR18 N V L N L T R L T F F F L I P L F I M I G C Y L V I I H N L L
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Rho E A A A Q Q Q E S A T T Q K A
S1P1 T R S R R L T F R K N I S K A S R S S E
CB2 Q H V A S L S G H Q D R Q V P G M A R M R L
Beta-2 R Q L Q K I D K S E G R F H V Q N L S Q V E Q D G R T G H G L R R S S K F C L K
MOR S V R M L S G S K E K D R N
GPR18 H G R T S K L K P K V
IC3 Loop
6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6
3 3 3 3 3 3 3 3 3 3 4 4 4 4 4 4 4 4 4 4 5 5 5 5 5 5 5 5 5 5 6 6
0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1
Rho E K E V T R M V I I M V I A F L I C W V P Y A S V A F Y I F T H Q G S N F G
S1P1 N V A L L K T V I I V L S V F I A C W A P L F I L L L L D V G C K V K T C D I
CB2 D V R L A K T L G L V L A V L L I C W F P V L A L M A H S L A T T L S D Q V
Beta-2 E H K A L K T L G I I M G T F T L C W L P F F I V N I V H V I Q D N L I R
MOR L R R I T R M V L V V V A V F I V C W T P I H I Y V I I K A L V T I P E T T F Q
GPR18 K E K S I R I I I T L L V Q V L V C F M P F H I C F A F L M L G T G E N S Y
TMH6 CWXP Motif EC3 Loop→
7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7
3 3 3 3 3 3 3 3 4 4 4 4 4 4 4 4 4 4 5 5 5 5 5 5 5 5
2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7
Rho P I F M T I P A F F A K S A A I Y N P V I Y I M M N K Q F R N C M L T T I C
S1P1 L F R A E Y F L V L A V L N S G T N P I I Y T L T N K E M R R A F I R I M S
CB2 K K A F A F C S M L C L I N S M V N P V I Y A L R S G E I R S S A H H C L A
Beta-2 K E V Y I L L N W I G Y V N S G F N P L I Y C R S P D F R I A F Q E L L C
MOR T V S W H F C I A L G Y T N S C L N P V L Y A F L D E N F K R C F R E F C I
GPR18 N P W G A F T T F L M N L S T C L D V I L Y Y I V S K Q F Q A R V I S V M L
TMH7 NPXXY Motif Elbow HX8
Rho C G K N P L G D D E A S A T V S K T E T S Q V A P A
S1P1 C C K C P S G D S A G K F K R P I I A G M E F S R S K S D N S S H P Q K D E G D N P
CB2 H W K K C V R G L G S E A K E E A P R S S V T E T E A D G K I T P W P D S R D L D L
Beta-2 L R R S S L K A Y G N G Y S S N G N T G E Q S G Y H V E Q E K E N K L L C E D L P G
MOR P T S S N I E Q Q N S T R I R Q N T R D H P S T A N T V D R T N H Q L E N L E A E T A
GPR18 Y R N Y L R S M R R K S F R S G S L R S L S N I N S E M L
C-Ter→
Rho T I M S S G N V N S S S
S1P1 D C
CB2 E D F V G H Q G T V P S D N I D S Q G R N C S T N D S L L
Beta-2 P L P
MOR
GPR18
